---
title: "Gimeracil - Malignant Tumor Of Stomach"
sidebar: mydoc_sidebar
permalink: db09257-mesh-d013274-1.html
toc: false 
---


Path ID: `DB09257_MESH_D013274_1`
{% include image.html url="images/db09257-mesh-d013274-1.png" file="db09257-mesh-d013274-1.png" alt="db09257-mesh-d013274-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C104201 | Gimeracil | Drug |
| UniProt:Q12882 | Dihydropyrimidine dehydrogenase | Protein |
| MESH:D005472 | Fluorouracil | Drug |
| MESH:D013274 | Malignant tumor of stomach | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Gimeracil | DECREASES ACTIVITY OF | Dihydropyrimidine Dehydrogenase |
| Dihydropyrimidine Dehydrogenase | DECREASES ABUNDANCE OF | Fluorouracil |
| Fluorouracil | TREATS | Malignant Tumor Of Stomach |
|---------|-----------|---------|

Comment: Gimeracil is available in combination with oteracil and tegafur within the commercially available product "Teysuno". Gimeracil's main role within Teysuno is to prevent the breakdown of Fluorouracil (5-FU), which helps to maintin high enough concentrations for sustained effect against cancer cells.

Reference: 
  - [https://go.drugbank.com/drugs/DB09257#BE0000960](https://go.drugbank.com/drugs/DB09257#BE0000960)
